{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T22:01:22Z","timestamp":1773525682987,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s13300-025-01705-y","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T03:27:56Z","timestamp":1741058876000},"page":"763-784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diabetes Educators: Understanding the Role of Finerenone in Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7562-3943","authenticated-orcid":false,"given":"Anne M.","family":"Kom\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7362-205X","authenticated-orcid":false,"given":"Anita","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Gee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5894-9054","authenticated-orcid":false,"given":"Klara R.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"1705_CR1","unstructured":"Centers for Disease Control and Prevention. National diabetes statistics report. 2023. Available from: https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html."},{"key":"1705_CR2","unstructured":"Centers for Disease Control and Prevention. About type 2 diabetes. 2023. Available from: https:\/\/www.cdc.gov\/diabetes\/about\/about-type-2-diabetes.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/diabetes\/basics\/type2.html."},{"issue":"1","key":"1705_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12963-018-0166-4","volume":"16","author":"J Lin","year":"2018","unstructured":"Lin J, Thompson TJ, Cheng YJ, et al. Projection of the future diabetes burden in the United States through 2060. Popul Health Metr. 2018;16(1):9.","journal-title":"Popul Health Metr"},{"key":"1705_CR4","unstructured":"Centers for Disease Control and Prevention. Chronic kidney disease. 2022. Available from: https:\/\/www.cdc.gov\/diabetes\/diabetes-complications\/diabetes-and-chronic-kidney-disease.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/diabetes\/managing\/diabetes-kidney-disease.html."},{"key":"1705_CR5","unstructured":"Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2023. 2023. Available from: https:\/\/www.cdc.gov\/kidney-disease\/php\/data-research\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/kidneydisease\/publications-resources\/ckd-national-facts.html."},{"key":"1705_CR6","unstructured":"National Institute for Health and Care Excellence. CVD prevention: chronic kidney disease detection and management. 2024. Available from: https:\/\/stpsupport.nice.org.uk\/cvd-prevention-ckd\/index.html."},{"issue":"1","key":"1705_CR7","first-page":"25","volume":"108","author":"A Whaley-Connell","year":"2011","unstructured":"Whaley-Connell A, Nistala R, Chaudhary K. The importance of early identification of chronic kidney disease. Mo Med. 2011;108(1):25\u20138.","journal-title":"Mo Med"},{"key":"1705_CR8","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice C. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S239\u2013S51.","DOI":"10.2337\/dc25-S011"},{"key":"1705_CR9","unstructured":"Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013S314."},{"key":"1705_CR10","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1\u2013S127.","DOI":"10.1016\/j.kint.2022.06.008"},{"issue":"9","key":"1705_CR11","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.2337\/dc21-0723","volume":"44","author":"D Alfego","year":"2021","unstructured":"Alfego D, Ennis J, Gillespie B, et al. Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database. Diabetes Care. 2021;44(9):2025\u201332.","journal-title":"Diabetes Care"},{"issue":"10","key":"1705_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","volume":"28","author":"L Blonde","year":"2022","unstructured":"Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan\u20132022 update. Endocr Pract. 2022;28(10):923\u20131049.","journal-title":"Endocr Pract"},{"key":"1705_CR13","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes. Chapter 3: Management of progression and complications of CKD. Kidney Int Suppl (2011). 2013;3(1):73\u201390.","DOI":"10.1038\/kisup.2012.66"},{"issue":"2","key":"1705_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"1705_CR15","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1007\/s12325-022-02223-0","volume":"39","author":"A Mima","year":"2022","unstructured":"Mima A. A narrative review of diabetic kidney disease: previous and current evidence-based therapeutic approaches. Adv Ther. 2022;39(8):3488\u2013500.","journal-title":"Adv Ther"},{"key":"1705_CR16","unstructured":"U.S. Food and Drug Administration. KERENDIA (finerenone) tablets, for oral use. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215341s001lbl.pdf."},{"key":"1705_CR17","unstructured":"U.S. Food and Drug Administration. INSPRA (eplerenone) tablets, for oral use. 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021437s013lbl.pdf."},{"key":"1705_CR18","unstructured":"U.S. Food and Drug Administration. ALDACTONE (spironolactone) tablets for oral use. 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/012151s075lbl.pdf."},{"issue":"9","key":"1705_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40264-014-0196-1","volume":"37","author":"C Ben Salem","year":"2014","unstructured":"Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-induced hyperkalemia. Drug Saf. 2014;37(9):677\u201392.","journal-title":"Drug Saf"},{"key":"1705_CR20","unstructured":"U.S. Food and Drug Administration. For healthcare professionals: FDA\u2019s examples of drugs that interact with CYP enzymes and transporter systems. 2024. Available from: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems."},{"key":"1705_CR21","unstructured":"Watson S. Your medicine could spike your potassium. WebMD. 2023. Available from: https:\/\/www.webmd.com\/a-to-z-guides\/medication-affect-potassium-levels."},{"issue":"6","key":"1705_CR22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"issue":"23","key":"1705_CR23","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"1705_CR24","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"key":"1705_CR25","unstructured":"ClinicalTrials.gov. A study to learn more about how well the study treatment finerenone works, how safe it is, how it moves into, through, and out of the body, and the effects it has on the body when taken with an ACE inhibitor or angiotensin receptor blocker in children with chronic kidney disease and proteinuria (FIONA). 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05196035."},{"key":"1705_CR26","unstructured":"ClinicalTrials.gov. A study to learn more about how safe the study treatment finerenone is in long-term use when taken with an ACE inhibitor or angiotensin receptor blocker over 18 months of use in children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuria (FIONA OLE). 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05457283."},{"key":"1705_CR27","unstructured":"ClinicalTrials.gov. Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) & mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to 40% (FINEARTS-HF). 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04435626."},{"issue":"6","key":"1705_CR28","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.3266","volume":"26","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, Ostrominski JW, Vaduganathan M, et al. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial. Eur J Heart Fail. 2024;26(6):1334\u201346.","journal-title":"Eur J Heart Fail"},{"key":"1705_CR29","unstructured":"ClinicalTrials.gov. A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease (FIND-CKD). 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05047263."},{"key":"1705_CR30","doi-asserted-by":"publisher","unstructured":"Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI, Lam CSP, Neuen BL, Sarafidis PA, Tuttle KR, Wanner C, Brinker MD, Dizayee S, Kolkhof P, Schloemer P, Vesterinen P, Perkovic V. FIND-CKD investigators. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrol Dial Transplant. 2025;40(2):308\u2013319. https:\/\/doi.org\/10.1093\/ndt\/gfae132.","DOI":"10.1093\/ndt\/gfae132"},{"key":"1705_CR31","unstructured":"ClinicalTrials.gov. A study to learn how well the study treatment finerenone works and how safe it is in people with long-term decrease in the kidneys' ability to work properly (chronic kidney disease) together with type 1 diabetes (FINE-ONE). 2024. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05901831."},{"issue":"9","key":"1705_CR32","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/ckj\/sfad073","volume":"16","author":"RM Zhang","year":"2023","unstructured":"Zhang RM. Single institution prescribing pattern of finerenone in patients with type 2 diabetes and\/or chronic kidney disease in the USA. Clin Kidney J. 2023;16(9):1538\u20139.","journal-title":"Clin Kidney J"},{"issue":"8","key":"1705_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221325","volume":"14","author":"CJ Sperati","year":"2019","unstructured":"Sperati CJ, Soman S, Agrawal V, et al. Primary care physicians\u2019 perceptions of barriers and facilitators to management of chronic kidney disease: a mixed methods study. PLoS\u00a0One. 2019;14(8):e0221325.","journal-title":"PLoS One"},{"issue":"7","key":"1705_CR34","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s13300-023-01416-2","volume":"14","author":"E Kelepouris","year":"2023","unstructured":"Kelepouris E, St Peter W, Neumiller JJ, Wright EE. Optimizing multidisciplinary care of patients with chronic kidney disease and type 2 diabetes mellitus. Diabetes Ther. 2023;14(7):1111\u201336.","journal-title":"Diabetes Ther"},{"issue":"4","key":"1705_CR35","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1177\/0145721720930959","volume":"46","author":"MA Powers","year":"2020","unstructured":"Powers MA, Bardsley JK, Cypress M, et al. Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Educ. 2020;46(4):350\u201369.","journal-title":"Diabetes Educ"},{"issue":"7","key":"1705_CR36","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.2337\/dc15-0730","volume":"38","author":"MA Powers","year":"2015","unstructured":"Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care. 2015;38(7):1372\u201382.","journal-title":"Diabetes Care"},{"issue":"5","key":"1705_CR37","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1177\/0145721713499412","volume":"39","author":"AL Martin","year":"2013","unstructured":"Martin AL, Warren JP, Lipman RD. The landscape for diabetes education: results of the 2012 AADE National Diabetes Education Practice Survey. Diabetes Educ. 2013;39(5):614\u201322.","journal-title":"Diabetes Educ"},{"issue":"5","key":"1705_CR38","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jcjd.2022.01.008","volume":"46","author":"L Chu","year":"2022","unstructured":"Chu L, Bhogal SK, Lin P, et al. Awareness of diagnosis and treatment of chronic kidney disease in adults with type 2 diabetes (AWARE-CKD in T2D). Can J Diabetes. 2022;46(5):464\u201372.","journal-title":"Can J Diabetes"},{"issue":"9","key":"1705_CR39","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1111\/dom.14455","volume":"23","author":"RE Powell","year":"2021","unstructured":"Powell RE, Zaccardi F, Beebe C, et al. Strategies for overcoming therapeutic inertia in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2021;23(9):2137\u201354.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1705_CR40","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/cd21-0089","volume":"40","author":"K Rodriguez","year":"2022","unstructured":"Rodriguez K, Ryan D, Dickinson JK, Phan V. Improving quality outcomes: the value of diabetes care and education specialists. Clin Diabetes. 2022;40(3):356\u201365.","journal-title":"Clin Diabetes"},{"key":"1705_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/DMSO.S40036","volume":"7","author":"SD Burke","year":"2014","unstructured":"Burke SD, Sherr D, Lipman RD. Partnering with diabetes educators to improve patient outcomes. Diabetes Metab Syndr Obes. 2014;7:45\u201353.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"4","key":"1705_CR42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2337\/dc23-1401","volume":"47","author":"CJ Hoogendoorn","year":"2024","unstructured":"Hoogendoorn CJ, Krause-Steinrauf H, Uschner D, et al. Emotional distress predicts reduced type 2 diabetes treatment adherence in the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2024;47(4):629\u201337.","journal-title":"Diabetes Care"},{"issue":"4","key":"1705_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15448","volume":"9","author":"E Baah-Nyarkoh","year":"2023","unstructured":"Baah-Nyarkoh E, Alhassan Y, Dwomoh AK, Kretchy IA. Medicated-related burden and adherence in patients with co-morbid type 2 diabetes mellitus and hypertension. Heliyon. 2023;9(4):e15448.","journal-title":"Heliyon"},{"issue":"1","key":"1705_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/0145721715619038","volume":"42","author":"K Capoccia","year":"2016","unstructured":"Capoccia K, Odegard PS, Letassy N. Medication adherence with diabetes medication: a systematic review of the literature. Diabetes Educ. 2016;42(1):34\u201371.","journal-title":"Diabetes Educ"},{"issue":"12","key":"1705_CR45","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390.","journal-title":"Diabetes Care"},{"key":"1705_CR46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12875-016-0407-1","volume":"17","author":"E Gucciardi","year":"2016","unstructured":"Gucciardi E, Espin S, Morganti A, Dorado L. Exploring interprofessional collaboration during the integration of diabetes teams into primary care. BMC Fam Pract. 2016;17:12.","journal-title":"BMC Fam Pract"},{"key":"1705_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03264-4","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M, Filippatos G, Claggett BL, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03264-4.","journal-title":"Nat Med"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01705-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01705-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01705-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:48:52Z","timestamp":1744872532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01705-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1705"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01705-y","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patrick Gee has received honoraria from FOUNTAIN EAC (Bayer International) Boehringer-Ingelheim and Evidation Health ProKidney Patient Advisory Board. Patrick is also a patient representative on the FOUNTAIN Executive Advisory Committee and ASN Diabetes Kidney Disease-Collaborative Task Force. Anita Yang has no conflicts of interest to disclose. Klara Klein has received consulting fees from Novo Nordisk and has received research-related contracts (paid to the institution) from Bayer, Boehringer-Ingelheim, Carmot, Diasome, Eli Lilly, Novo Nordisk, Rhythm Pharmaceuticals, and vTv Therapeutics. Anne M. Kom\u00e9 has received consulting fees from Camurus, Dexcom, and Lexicomp\u2014Wolters Kluwer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}